Quickview - Lixi prospects see saw

Monday, Feb 18 2013 by

Feb 18th 2013 - Edison Investment Research today published a report on quickview entitled "Lixi Prospects See Saw". In summary, the report says:

A surprise regulatory setback for Novo Nordisk’s Tresiba has suddenly improved the prospects for Zealand’s key partnered programme just days after they were dashed. Thus, the setback that came with the disclosure by Sanofi of a delay in the development of the Fix-Flex combination product has been somewhat offset by the delay to Novo’s competing insulin/GLP-1 agonist combination, as a result of the FDA’s rejection of Tresiba. While uncertainty remains about the development timelines for Sanofi’s combination product, the shape of the future diabetes landscape has now shifted back in its (and thus Zealand’s) direction. Furthermore, after a 20% fall, Zealand’s share price has yet to reflect this new situation.




About Edison Investment Research

Edison Investment Research

Follow

Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »